Literature DB >> 11289058

The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.

H Mori1, H Ikegami, Y Kawaguchi, S Seino, N Yokoi, J Takeda, I Inoue, Y Seino, K Yasuda, T Hanafusa, K Yamagata, T Awata, T Kadowaki, K Hara, N Yamada, T Gotoda, N Iwasaki, Y Iwamoto, T Sanke, K Nanjo, Y Oka, A Matsutani, E Maeda, M Kasuga.   

Abstract

The allele frequencies for a Pro12-->Ala substitution in peroxisome proliferator-activated receptor-gamma differ among ethnic groups, and its relationship with diabetes and associated diseases is controversial. The prevalence of this polymorphism and its effects on clinical characteristics have now been evaluated with a large number of Japanese individuals with type 2 diabetes (n = 2,201) and normal control subjects (n = 1,212) recruited by 10 institutions located in seven different cities in Japan. The allele frequency for the Ala12 variant was significantly lower in the type 2 diabetic group than in the control group (2.39 vs. 4.13%, P = 0.000054). However, compared with subjects without the Ala12 variant, the diabetic subjects with this variant exhibited a significantly higher serum concentration of total cholesterol (P = 0.001), manifested a reduced capacity for insulin secretion as evaluated by homeostasis model assessment (P = 0.007), and tended to possess a higher level of HbA1c. These data suggest that the Ala12 variant is associated with a reduced risk for the development of diabetes in the general population, but that it may be also a risk factor for insulin deficiency and disease severity in individuals with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289058     DOI: 10.2337/diabetes.50.4.891

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  66 in total

Review 1.  Candidate genes for type 2 diabetes.

Authors:  Hemang Parikh; Leif Groop
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

2.  Genetic variants in the calpain-10 gene and the development of type 2 diabetes in the Japanese population.

Authors:  Naoko Iwasaki; Yukio Horikawa; Takafumi Tsuchiya; Yutaka Kitamura; Takahiro Nakamura; Yukio Tanizawa; Yoshitomo Oka; Kazuo Hara; Takashi Kadowaki; Takuya Awata; Masashi Honda; Katsuko Yamashita; Naohisa Oda; Li Yu; Norihiro Yamada; Makiko Ogata; Naoyuki Kamatani; Yasuhiko Iwamoto; Laura Del Bosque-Plata; M Geoffrey Hayes; Nancy J Cox; Graeme I Bell
Journal:  J Hum Genet       Date:  2005-02-05       Impact factor: 3.172

3.  Maternal urinary phthalate metabolites in relation to gestational diabetes and glucose intolerance during pregnancy.

Authors:  Rachel M Shaffer; Kelly K Ferguson; Lianne Sheppard; Tamarra James-Todd; Samantha Butts; Suchitra Chandrasekaran; Shanna H Swan; Emily S Barrett; Ruby Nguyen; Nicole Bush; Thomas F McElrath; Sheela Sathyanarayana
Journal:  Environ Int       Date:  2019-01-07       Impact factor: 9.621

4.  No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families.

Authors:  H Yue; J-W He; H Zhang; W-W Hu; Y-Q Hu; M Li; Y-J Liu; S-H Wu; Z-L Zhang
Journal:  Osteoporos Int       Date:  2009-07-31       Impact factor: 4.507

Review 5.  The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis.

Authors:  Tingting Li; Yun Shi; Jieyun Yin; Qin Qin; Sheng Wei; Shaofa Nie; Li Liu
Journal:  Int Urol Nephrol       Date:  2014-09-28       Impact factor: 2.370

6.  Influence of peroxisome proliferator-activated receptor (PPAR)gamma Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Masakatsu Nakamura; Fangyu Wang; Naoko Maruyama; Yoshio Kamiya; Masahiko Nakamura; Hiroshi Fujita; Mitsuo Nagasaka; Masami Iwata; Kazuya Takahama; Makoto Watanabe; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

7.  Association of peroxisome proliferator-activated receptorγ gene Pro12Ala and C161T polymorphisms with cardiovascular risk factors in maintenance hemodialysis patients.

Authors:  Feng Liu; Xiaobin Mei; Yingying Zhang; Hualin Qi; Jun Wang; Yi Wang; Wei Jiang; Xintian Zhang; Haidong Yan; Shougang Zhuang
Journal:  Mol Biol Rep       Date:  2014-08-06       Impact factor: 2.316

8.  Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients.

Authors:  Limei Liu; Taishan Zheng; Feng Wang; Niansong Wang; Yanyan Song; Ming Li; Lifang Li; Jiamei Jiang; Weijing Zhao
Journal:  Diabetes Care       Date:  2009-10-16       Impact factor: 19.112

9.  Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.

Authors:  S Ereqat; A Nasereddin; K Azmi; Z Abdeen; R Amin
Journal:  PPAR Res       Date:  2009-10-25       Impact factor: 4.964

10.  Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.

Authors:  Salvatore De Cosmo; Nicola Motterlini; Sabrina Prudente; Fabio Pellegrini; Roberto Trevisan; Antonio Bossi; Giuseppe Remuzzi; Vincenzo Trischitta; Piero Ruggenenti
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.